Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells

NCT00077415 is registered in ClinicalTrials.gov with Cancer Therapeutics Research Group as lead sponsor.

NCT NCT00077415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00077415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells
Lead sponsor
Cancer Therapeutics Research Group
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
February 29, 2008
Enrollment
31 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer